I currently work for a company in its death throes. The entire engineering dept, save for me, has quit or retired and none have been replaced. Every day I trudge into work steeling myself, waiting to be assaulted by accusations of incompetence, laziness, and poor work ethic. The state of the job market is the only thing keeping me working here still. Every morning upon entering the building my bowels flinch and my stomach churns. I feel like I’m under assault. Constantly. Every. Single. Day. I had a coworker a while ago who coined a phrase,”Give-a-Shittedness Quotient” to describe the amount of concern an employ had remaining for providing a job well done. Short-timers about to retire famously struggle to give any more shits. A person who has submitted their 2-weeks notice similarly will phone it in. High School seniors, already accepted to university - pending successful graduation - famously suffer from senioritis. I am not in those situations yet I find myself struggling to give a shit. I struggle to drag myself to work. No one knows what I do or why. No one cares if I do well or not. To the contrary, everyone seems to default to me struggling to keep up for some unknown reason. Nevermind that I fill two different positions, each a distinct title that would ordinarily be a full time job by itself. In my engineer role. I am all that remains of a 5-person department. In my department manager role, my department has been cut in half, MORE THAN DECIMATED. I can’t imagine why I, or my department, might be struggling to keep up. I explain all this so it might be understood when I say I have Occupational PTSD, self-diagnosed of course. I have trouble sleeping, eating, my temper is short and I fear I’m harming close relationships because my fight/flight response has been on high-alert for months. I’m applying for jobs only tangentially related to my training or experience, willingly accepting 20-30% pay cuts if necessary…but the local job market is so broken there’s almost nothing even close to what I need.
Wednesday, July 09, 2025
Monday, April 05, 2021
Tesla to the Moon...
When people ask how far behind other automakers are, perhaps this will put it into perspective. GM announced that they set a record for sales of their lone electric vehicle, the Chevy Bolt in Q1 2021. They sold 9000 units in Q1, a nearly 54% increase year over year. Tesla, for comparison, grew their production capacity year over year by 109% and produced 189,000 EVs in Q1. Tesla is buying mines to produce lithium, nickel, and graphite for their batteries because they are materially constrained in their battery factories. GM is about 2-3 years away from completion of their first battery factory. By that time Tesla will have battery factories in CA, NV, TX, Germany, and China, all producing batteries in quantities that dwarf GMs capacity, and it still won't be enough. VW sales of their ID3 vehicle are doing well compared to GM, with sales of 28k, but 1/4 of those were sold to VW itself, so not as good as it may appear. The EV revolution is here, and it's happening WAY faster than people in the US think. By 2025 they'll have a hard time buying anything other than an EV.
GM Posts Q1 '21 record EV sales:
https://insideevs.com/news/498574/us-chevrolet-bolt-sales-q12021/
VW sells thousands of EVs to VW:
https://cleantechnica.com/2021/02/19/how-many-volkswagen-id3-sales-volkswagen-sales-to-itself/
Friday, February 26, 2021
Long time no talk
It's been a long time since I posted anything on here. Does anyone still read blogs? 2020 has been a dumpster fire of a year.
Monday, July 17, 2017
Chevy Volt...the Unsung Hero of the GM Stable
![]() |
| GM EV1 |
![]() |
| Tesla Roadster |
| Bob Lutz w/ Chevy Volt Prototype |
| Chevy Volt |
GM grossly over engineered the vehicle. They recognized that the Lithium Polymer battery was a weak spot in the design because there wasn't much known yet about how the large batteries behaved or how long they'd last. GM tested the batteries extensively and found that extreme swings in temperature and the number of full charge/discharge cycles were among the most significant factors affecting battery performance and longevity. To get around this limitations, engineers gave the Volt about 20-30% more battery than it actually needed. This meant that it would never fully charge/discharge. The battery would never need to work very hard. To keep it at a stable temperature, a liquid cooling system was used to regulate the temperature. All rechargeable batteries will degrade eventually. As the battery degrades, the controls in the Volt make more of the battery's capacity available to ensure that the user doesn't experience loss of capacity. As of 8/16, GM had zero reported cases of battery replacement due to loss of general capacity. There have been a few replaced due to component failures, but none that have suffered general capacity failure. The Volt has a small but extremely loyal, and satisfied, user base. The Volt has been ranked high or highest in customer satisfaction since its introduction, crash test ratings have similarly been among the best. Fuel economy obviously scores well. Reliability is the one that surprised me. For all the high-tech stuff in the Volt it has proven to be a surprisingly reliable car. Sure it's had a few quirks to work out, but this is new technology in uncharted waters, some bumps are to be expected.
So why doesn't everyone own a Volt!?!?! The Volt commanded a high price initially at $40k+ and had the misfortune of being released as GM was declaring bankruptcy from the largest financial collapse since the Great Depression. Bob Lutz was shown the door as part of GMs restructuring and the bailout by the US federal government. The Volt was his "swan song". The Volt received a flurry of publicity initially with high-profile celebrities making Volt purchases. The $40k price tag was a significant hurdle. The pluses outweighed the cons for the Volt though, and it sold reasonably well. Over time, the price dropped until it could be purchased for about $30k. Better still, the federal government created an income tax credit for purchasers of EVs based on EV range. The Volt is eligible for the full credit of $7500 making the price drop into the low to mid $20k range. Eventually, when enough are sold, the credit will go away and the Volt's price will return to the $30k range. It is still the best selling plug-in hybrid electric vehicle (PHEV). In 2016 a second generation Volt was released that provided a more powerful motor, more electric range and some additional features added to improve the Volt's standing. All of this adds up to a fantastic car, at a reasonable price that no one seems to know about. Those who do know about it generally love it and won't shut up about it. It's only real competition is from the Prius Prime plugin.
| Prius Prime PHEV |
Friday, March 11, 2016
Juggling Benjamins
Monday, February 08, 2016
Guns, Guns, and More Guns
| Umarex PX4 Storm |
| Savage Model 64 .22LR |
Wednesday, September 09, 2015
The Stock Market is Baffling
Friday, January 16, 2015
Genspera (GNSZ)
Press Release:
SAN ANTONIO, Jan. 16, 2015 /PRNewswire/ -- GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California.The Phase II results demonstrated that mipsagargin appears to be effective and is well-tolerated by HCC patients. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA), which is highly expressed in tumor vasculature and prostate cancer cells. The Phase II study results (n=25) demonstrate that the prodrug effectively stabilizes progression of HCC by reducing blood flow within tumors while not affecting blood flow within normal tissues."We are very encouraged with the positive results from this Phase II trial that demonstrate the tolerability and show indications of effectiveness of mipsagargin in advanced liver cancer patients," said Craig Dionne, PhD, chief executive officer at GenSpera. "Mipsagargin is a first-in-class agent with a novel mechanism of action that is unlike any other drug being tested in patients with advanced liver cancer. Based on the results of this study, we intend to move forward with a large, global Phase III trial."Mipsagargin's targeted approach differs from other vascular targeting agents by destroying established tumor vasculature rather than slowing the growth of new tumor blood vessels. The PSMA-targeting agent is designed to minimize side effects commonly observed with other therapies, while maximizing activity against tumors."These results demonstrate the potential that mipsagargin has to treat one of the world's deadliest cancers," said Devalingam Mahalingam, MD, PhD, an oncologist at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio and principal investigator of the study. "In addition to observing prolonged disease stabilization in some patients, we noted anecdotal evidence that patients had improved performance status with much less fatigue and side effects associated with other anti-cancer therapeutics."With Phase II complete, GenSpera is designing a large, international Phase III study which will further define the anti-tumor potential of mipsagargin in liver cancer patients. More information on mipsagargin (G-202) can be found at www.genspera.com.Hepatocellular carcinoma is the most common form of cancer that originates in the liver. In the United States, more than 33,000 new cases will be diagnosed in 2015. Globally, liver cancer is a primary public health issue with more than 700,000 people diagnosed and more than 600,000 deaths annually. It is the most common type of cancer in Southeast Asia and sub-Saharan Africa. A liver cancer diagnosis is often subsequent to other liver disease, making treatment of a highly compromised patient population particularly challenging.Data Establishes Foundation for Continued InvestigationThe Phase II study (Abstract #301) of mipsagargin was a multi-site, single arm study designed to assess time to progression and response rate to treatment. The study measured disease progression in 25 patients with advanced-stage liver disease and poor liver reserves who had failed first line treatment with sorafenib. Patients were administered episodic dosing of mipsagargin on the first three days of each treatment cycle. Study participants experienced a median time to progression of 4.2 months, nearly twice the time demonstrated in prior studies with placebo or ineffective agents. Thirty-five percent of patients received 5 or more cycles of treatment with an average time on study of 7.1 months. Additionally, mipsagargin demonstrated decreased blood flow in liver tumors as measured by DCE-MRI.About GenSperaGenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for the targeted release of drug candidates within tumors. GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the US Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).
Sunday, August 17, 2014
Being Alone
Wednesday, May 28, 2014
Where's the Inflation?
Sunday, February 09, 2014
2 Days in the Valley
I'm feeling a bit isolated recently. I don't really get out much and I don't really have any close friends to do much of anything with. Everything that I want to do seems to be scheduled specifically to coincide with every single thing that my wife has scheduled for several months in advance. Hockey on Monday? Wife has a poetry group. Hockey on Thursday? Wife has a book club. Hockey on Sunday? Wife has weekend away / some writing workshop / some random thing that has her out of town until just after I need to leave to get to hockey on time. Beer and Science Night? There's always something that keeps me from going. It's getting really frustrating.
Tuesday, August 07, 2012
Hard About! Hoist the main sail!
Monday, February 13, 2012
Monday, February 06, 2012
Personal rate of return 01/31/2012
1 year : 3.3%
3 years : 19.8%
5 years : 2.5%
That doesn't mean that I made a fortune in 2009, but rather that I lost a fortune in 2008 and things recovered in 2009-2011...and then some. But in addition to that, I maxed out my IRA contributions, started a ROTH IRA, and made some large (for me) investments in individual stocks while things were down. I bought GE, C, BAC, USB, and F all at incredible discounts. GE is now almost 100% above where I bought it at. C continued to tank and is still in negative territory, but I'm confident that it will recover eventually and earn a profit for me. F is doing well. BAC was doing well, then tanked. I don't know when or if that will recover, but if it does I should do pretty well there too.
Friday, January 21, 2011
I remember a time not that long ago, maybe 3-5 years ago, when I liked my job and looked forward to going in. Now I feel like it is death by a thousand paper cuts. In the last 3 years my responsibilities have tripled, my pay has been flat, and I've lost vacation time. My benefits of been reduced. When I do take a vacation, I'm still on-call. When I wake in the morning I can feel my psychosomatic gland whipping up a flu, sore throat, stomach ache, head ache, etc in an effort to convince me to call in sick. I used to tell myself "be thankful, you still have a job". Now I'm starting to think that my job is killing me. We shouldn't live to work. We should work to live. My job is not enhancing my life in any way. It is interfering with my life and my health. The worst bit though is that I feel trapped, helpless and powerless. I can not just look in the paper and get another job. They don't exist. So on I go a little closer to giving up everyday. Damned Protestant Work Ethic. Mazlow would use me as an example. At 1 day shy of 36 I'm clinging tenaciously to the first stage of Mazlow's Hierarchy and I'm pretty sure that my job is trying to take that from me too.
Friday, February 26, 2010
Tuesday, January 12, 2010
http://news.cnet.com/8301-13860_3-10433198-56.html?part=rss&subj=news&tag=2547-1_3-0-20
http://www.elevation.com/EP_port.asp
http://www.elevation.com/EP_IT.asp?id=112
http://investor.palm.com/committees.cfm
I do find it to be interesting that U2 has shilled for both Apple and RIM (Blackberry), but not Palm, despite the fact that Bono is a major shareholder of Palm through Elevation Partners.
Sunday, December 27, 2009
Thursday, December 03, 2009

Ender is just a few days over 4 months old. As he stared up at me while sucking down yet another bottle this morning I thought 'this is probably as close to being a god as I'll ever come'. At the same time I felt utterly insignificant. I had helped to create a new life--something that has been aptly referred to as the 'Miracle of Life'-- yet I am well aware that this "miracle" has occurred at least 7-10 billion times in the history of the world. That makes it hardly a rare occurrence but it doesn't make it any less a miracle somehow.
In the book 'The Age of Intelligent Machines' Ray Kurzweil argues that humans build upon their technological developments and this causes the technological developments to increase in frequency. He argues that within my lifetime computers will exist that exceed the storage capacity of the human brain and which will also exceed the computational power of the human brain. That doesn't mean that a smart machine is anywhere on the horizon in my opinion (though Ray Kurzweil disagrees). Ender was born as an essentially unfinished fetus with a brain that was a blank slate. For three months he finished developing while outside the womb and NOW he is starting to become a human. I see the scientific process at work in his brain before he even knows what science is. Observe, create a theory, experiment, review, integrate results into next experiment, form new theory, repeat. He is creating a framework from which to hang his personality on. He is learning how to learn. Think about that for a few seconds. It is a chicken/egg conundrum yet he doesn't let that bother him in the least. Simple tasks such as watching my wife drink from a glass are revelations to him. From that single observation he is learning about fluid dynamics, gravity, muscle control, biology, leverage and who-knows-what-else. It is really amazing to see how a human brain learns how to learn. When a computer finally learns how to learn, beware -- Terminator 4(5?) can't be far off in the future.
Monday, November 02, 2009
Today we leave for Seattle on the first leg of our trip back to Pittsburgh. We're staying overnight with a friend who lives very close to SeaTac. Then we leave in the morning for Pittsburgh. It is the first time we're travelling with the little man. We will be just as confused by the experience as he will be, maybe more so. There are different rules for the FAA, airline, TSA, and the 'unspoken' rules for the random TSA inspectors. I'm sure that at some point someone will make us get rid of something, but we don't know what, so we're trying to plan for every contingency to guarantee that we have diapers and formula no matter what they ask us to leave behind. We have to arrange to have car seats available everywhere. At least this will be the first flight where the screaming inconsolable child that everyone curses will be MINE! Mwah ha ha ha ha!


